| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2019 | Feb 12, 2019 | Gossamer Bio, Inc. | Director | Buy | 95.0 | +7,200 | 100.00% | ✗ | $115.2K |
| Aug 7, 2017 | Aug 9, 2017 | Jazz Pharmaceuticals plc | COO | Sell | 22.5 | -978 | -1.85% | ✗ | $152.1K |
| Mar 6, 2017 | Mar 8, 2017 | Jazz Pharmaceuticals plc | COO | Sell | 22.5 | -1,793 | -3.28% | ✗ | $238.1K |
| Feb 27, 2017 | Mar 1, 2017 | Jazz Pharmaceuticals plc | COO | Sell | 20.0 | -2,507 | -5.32% | ✗ | $343.4K |
| Jan 18, 2017 | Jan 19, 2017 | Jazz Pharmaceuticals plc | COO | Sell | 26.3 | -4,000 | -7.83% | ✓ | $515K |
| Aug 7, 2016 | Aug 10, 2016 | Jazz Pharmaceuticals plc | COO | Sell | 15.0 | -9,543 | -15.75% | ✓ | $1.4M |
| Apr 12, 2016 | Apr 13, 2016 | Jazz Pharmaceuticals plc | COO | Sell | 30.0 | -4,000 | -6.20% | ✓ | $547.9K |
| Apr 12, 2016 | Apr 12, 2016 | Spyre Therapeutics, Inc. | Director | Buy | 95.0 | +7,000 | 100.00% | ✗ | $70K |
| Mar 7, 2016 | Mar 9, 2016 | Jazz Pharmaceuticals plc | COO | Sell | 22.5 | -1,550 | -2.35% | ✗ | $198.2K |
| Feb 29, 2016 | Mar 2, 2016 | Jazz Pharmaceuticals plc | COO | Sell | 22.5 | -939 | -1.40% | ✗ | $114.2K |
| Feb 25, 2016 | Feb 29, 2016 | Jazz Pharmaceuticals plc | COO | Sell | 95.0 | +8,269 | 14.09% | ✗ | $91.4K |